The underlying mechanisms by which tumor cells are resistant to CTL-mediated apoptosis are not clear. Using a human model of B-cell non-Hodgkin's lymphoma (B-cell NHL), we show that intratumoral T reg cells inhibit the proliferation and granule production of activated autologous infiltrating CD8 + T cells. Our results also show that degranulation and subsequent cytotoxic activity of infiltrating CD8 + T cells exposed to lymphoma B cells is completely attenuated by the presence of intratumoral T reg cells. Furthermore, we show that increased numbers of intratumoral T reg cells correlates with the number of CD8 + T cells in biopsy specimens from patients with B-cell NHL, supporting the in vitro findings that intratumoral T reg cells inhibit proliferation of infiltrating CD8 + T cells. Taken together, these data indicate that human lymphoma B cells are sensitive to autologous CTL-mediated cell death but are protected by the inhibitory function of intratumoral T reg cells.
Introduction
B-cell non-Hodgkin's lymphoma (NHL) is characterized by an accumulation of malignant monoclonal B cells arrested at different stages of differentiation. The microenvironment in which NHL is typically found consists of secondary lymphoid organs that are replete with immune cells. Although numerous studies have focused on the biology of the malignant B cell, there is now a growing literature suggesting that tumor infiltrating immune cells may also play a role in determining the outcome of patients with B-cell NHL (1, 2) . The cellular component of NHL consists predominantly of malignant B cells, T cells, and monocytes. The specific role of intratumoral T cells and their significance in the pathogenesis of the NHL is not well understood, but there is increasing evidence indicating their relevance (3) . In the nonmalignant scenario, T cells play a critical role in regulation of the immune response; yet, in the tumor microenvironment, these same T cells are unresponsive and fail to function appropriately (4, 5) . The presence of an immunosuppressive network within the tumor microenvironment may therefore allow tumor cells to grow unchecked by the immune system. In murine models of NHL, it has been shown that induction of antigen-specific T-cell tolerance is one mechanism by which antitumor immunity is disrupted (6) (7) (8) .
Other underlying mechanisms that foster a poor immune response include reduced quality of tumor-associated antigen (TAA) presentation, aberrant cytokine and inflammatory molecule expression, and a shift in costimulatory and coinhibitory molecule expression by TAA-presenting, antigen-presenting cells (9) .
An additional mean by which tumors escape immunosurveillance is through an imbalance in the number of regulatory T cells (T reg cells). An accumulation of T reg cells in the tumor microenvironment has been shown to have a significant effect on the functional properties of infiltrating CD4 + T cells and patient outcome (3, 10, 11) . In previous work, we have found that T reg cells (CD4 + CD25 + T cells with intracellular Foxp3 and CTLA-4 expression) were overrepresented in the tumor sites of NHL. We also found that nearly all CD4 + CD25 + T cells isolated from NHL tumors expressed Foxp3, and that intratumoral T reg cells could suppress the functional capabilities, proliferation, and production and secretion of IFN-g and interleukin-4, of autologous infiltrating CD4 + CD25
À T cells (3) . In accordance with this data, Zhou et al.
showed in a murine lymphoma model that tumor induced suppression of CD4 + T cells was regulated in part by expansion of the T reg pool (12) . Taken together, these data suggest that the presence of T reg cells within the tumor microenvironment results in a dampening of the CD4 + T-cell response. What remains unanswered is whether or not T reg cells directly affect tumorassociated CD8 + CTL (CD8 + CTL) function, and more importantly, the ability of CTLs to kill autologous tumor cells.
Previous studies have shown that lymphoma B cells are resistant to CTL-mediated cell death (3) (4) (5) , and this has been attributed to changes in their genetic or protein expression profile (3-5, 13, 14) as well as to abnormal CTL function (15) (16) (17) . Additionally, there is accumulating data suggesting that T reg cells are capable of inhibiting CD8 + T cells under different pathologic conditions such as infection (18, 19) or allograft transplantation in vivo (20, 21) . Murine studies indicate that T reg cells can abrogate CD8 + T cell-mediated tumor rejection by specifically suppressing cytotoxicity of expanded CD8 + cells (22) (23) (24) . However, little is known about the effect of intratumoral T reg cells on CTL activity in a human NHL model.
To determine the significance of T reg cells on CD8 + T-cell function, we characterized the role of T reg cells in modulating antitumor responses. We show that intratumoral T reg cells isolated from NHL tumors completely inhibit proliferation and granule production of infiltrating CD8 + T cells obtained from the same tumor specimen. Suppression of CD8 + function by T reg cells results in an inability of tumor specific CD8 + T cells to kill autologous tumor cells. We therefore show for the first time that infiltrating CD8 + T cells from NHL tumors are functional, and that their activity is suppressed when T reg cells are present.
Materials and Methods
Patient samples. Patients providing written informed consent were eligible for this study if they had a tissue biopsy that on pathologic review showed B-cell lymphoma and adequate tissue to perform experiments. The biopsy specimens were reviewed and classified using the WHO Lymphoma classification. This study was approved by the Institutional Review Board of the Mayo Clinic/Mayo Foundation. Biopsy specimens from a total of 28 patients were used for the study (see Table 1 ).
Cell isolation and purification. . All sections were stained with hematoxylin and rinsed well in tap water. All slides were observed with light microscopy (Olympus AX70, Â200/aperture 0.46, Â400/aperture 0.75, Â600/ aperture 0.80; Olympus America, Melville, NY) with images captured with a SPOT RT camera and software (Diagnostic Instruments, Burlingame, CA).
Flow cytometry and intracellular staining. Cells (1 Â 10 6 ) were washed in PBS containing 0.5% bovine serum albumin and incubated with CD3-, CD4-, CD8-, CD19-, and CD25-specific fluorochrome-conjugated antibodies and analyzed on a FACSCalibur flow cytometry (Becton Dickinson, San Diego, CA). For intracellular staining of perforin (PFN) and granzyme B (GzmB), cells were fixed with 2% paraformaldehyde for 15 minutes, washed, permeabilized with 0.5% saponin for 30 minutes, and stained with FITC-CD3, Percp-CD8, and phycoerythrin-conjugated PFN (1:1,000 dilution; BD PharMingen, San Diego, CA), or APC-conjugated Gzm B (1:200 dilution; GB12; Caltag, Burlingame, CA) for 30 minutes at 4jC. After washing, cells were analyzed by flow cytometry. Isotype controls were done for each sample.
Carboxyfluorescein succinimidyl ester labeling and T-cell proliferation assay. Cells were washed, counted, and resuspended at 1 Â 10 7 /mL in PBS. A stock solution of carboxyfluorescein succinimidyl ester (CFSE; 5 mmol/L) was diluted 1:100 with PBS and added to the cells for a final concentration of 5 Amol/L. After 10 minutes at 37jC, cells were washed thrice with 10 volumes of PBS containing 10% fetal bovine serum. CFSE-labeled responding cells were cocultured with or without stimulating cells in the presence or absence of phytohemagglutinin (PHA; 2.5 Ag/mL) at 37jC and 5% CO 2 . Cells were harvested at day 3, washed, and stained with fluorochrome-conjugated antibodies for detection of surface markers for 30 minutes at 4jC. Cells were analyzed by flow cytometry. The percentage of CFSE dim was measured and calculated as the percentage of proliferated cells. Degranulation assay. Degranulation assays were done by determining CD107a surface mobilization on infiltrating CD8 + T cells from B-cell NHL during activation or exposure to lymphoma B cells. The assay was set up based upon a similar approach described by Betts et al. with a few modifications (25) . Lymphoma B cells were plated at 2 Â 10 5 per well in a 48-well plate and incubated at 37jC for overnight. On the next day, the culture supernatant was removed from the wells, and the effector cells were added to the wells at various effector/target (E/T) ratios. cocultured with intratumoral T reg cells in the presence of PHA (2.5 Ag/mL) for 5 days. Control wells containing either only effector cells or tumor targets were also set up with each assay. CD107a-PE (10 AL) was added to each well at the same time as addition of effector cells. The plate was then centrifuged for 3 minutes at 1,000 rpm to facilitate immediate contact between the effector cells and the tumor targets at the bottom of the wells and incubated at 37jC for overnight. At the end of the incubation period, the cells were stained with anti-human CD8-Percp antibody and analyzed using a FACSCalibur flow cytometry. Cytotoxicity assay. A flow-based cytotoxicity assay was used to measure in vitro cellular cytotoxicity of infiltrating CD8 + T cells against lymphoma B cells as previously described (26, 27) . Target + T cells cocultured with CD4 + CD25 +/À T cells were subjected to CD8-positive selection on the day CD8 + T cells were exposed to target cells. In parallel, target cells were incubated alone to measure basal apoptosis. Immediately before analysis, 1 Ag/mL ( final concentration) of 7-amino-actinomycin D (7-AAD; Calbiochem, La Jolla, CA) was added to each sample and incubated for 20 minutes at 4jC in the dark. The percentage of apoptotic (7-AAD lo +7-AAD hi ) cells are used to calculate the percentage of specific lysis according to the following formula: % specific lysis = 100 Â (% sample lysis À % basal lysis) / (100 À % basal lysis). Sample lysis is the cell lysis in the presence of effectors at a given E/T ratio, and basal lysis is the cell lysis in the absence of effectors.
Statistical analysis. Fisher's exact test was used to compare differences in nominal variables, whereas the rank sum test, paired Student's t test, or the Kruskal-Wallis test was used for continuous variables. P < 0.05 was considered significant. Direct correlation between percentage of CD4 + CD25 + T cells and CD8 + T cells was done with the use of regression analysis.
Results
Foxp3 expression in B-cell NHL. In previous work, we identified a subset of CD4 + CD25 + Foxp3 + T cells in the biopsy specimens of B-cell NHL by flow cytometry (3) . In the present study, we did immunohistochemistry to confirm the presence of regulatory T cells in NHL tissue. A series of tissue slides (serial sections) from NHL tumor biopsy specimens (n = 11) were stained with antibodies specific for Foxp3, CD25, CD4, CD8, CD3, and CD20. Each specimen also stained with an isotype control and minimal to no staining was detected (data not shown). As shown in a representative case in Fig. 1 + T cells is critical to their ability function as cytotoxic T cells. Therefore, our next goal was to determine the effect of intratumoral T reg cells on cytolytic granule production by infiltrating CD8 + T cells. First, we determined the intracellular expression profile of PFN and GzmB in infiltrating CD8 + T cells from fresh biopsy specimens using multicolor intracellular staining (Fig. 3A) . Mononuclear cells isolated from NHL biopsy specimens were costained with antibodies specific to CD3, CD8, and PFN or GzmB. Fig. 3A , PFN or GzmB were exclusively expressed by infiltrating CD8 + T cells. PFN and GzmB expression could be detected individually and in some cases was found to be coexpressed. Data acquired from 25 fresh NHL samples indicate that the mean percentage of CD8-positive T cells that were PFN + was 10% (10 F 6%), GzmB + 38% (38 F 15%), and PFN + GzmB + 8% (8 F 6%; Fig. 3B ). These data suggest that a majority (>50%) of resting infiltrating CD8 + T cells do not express PFN or GzmB.
cells. As shown in
Next, we determined the influence of T reg cells on PFN and GzmB expression ( Fig. 3C and D) . Therefore, we cultured infiltrating CD8 + T cells alone, with intratumoral T reg cells, or with infiltrating CD4 + CD25
À T cells at a ratio of 4:1 in the presence or absence of PHA (n = 3). The cells were then subjected to intracellular staining for PFN and GzmB and analyzed by flow cytometry. As shown in Fig. 3C and D, 1% of resting purified infiltrating CD8 + T cells expressed intracellular PFN and 3% expressed GzmB. As expected, activation with PHA dramatically increased intracellular expression of PFN from 1% to 18% and GzmB from 3% to 99%. When CD8 + T cells were cocultured with intratumoral T reg cells, we saw attenuation of activation-induced expression of PFN from 18% to 5%. Similarly, GzmB expression was decreased from 99% to 12%. In the presence of infiltrating CD4 + CD25 À T cells, activationinduced expression of PFN and GzmB by infiltrating CD8 + T cells remained unchanged. These findings indicate that intratumoral T reg cells strongly inhibit the production of PFN and GzmB granules by infiltrating CD8 + T cells in B-cell NHL. Intratumoral T reg cells inhibit the degranulation of infiltrating CD8 + T cells in B-cell NHL. We next sought to determine the effect of intratumoral T reg cells on granule release by infiltrating CD8 + T cells. Degranulation is an essential mechanism by which CD8 + T cells lyse tumor cells, and it has been shown that granule release is accompanied by the surface mobilization of CD107a (lysosome associated-membrane protein-1) on cytolytic cells. Therefore, CD107a surface expression has been used as a surrogate marker of degranulation by cytolytic cells such as natural killer cells (28, 29) and CTLs (25, 30) . When we examined CD107a expression on resting or PHA activated infiltrating CD8 + T cells, we saw that a negligible amount of surface expression was detectable on resting cells. However, activation of infiltrating CD8 + T cells using PHA increased the surface expression of CD107a (Fig. 4A) . No effect on CD107b expression was seen (data not shown). CD107a surface expression on infiltrating CD8 + T cells reached its highest level after 5 hours of stimulation and declined to undetectable levels after 24 hours. This is in agreement with the observation that CD107a surface expression is transient (31) . Furthermore, when infiltrating CD8 + T cells were exposed to lymphoma B cells (Raji cells), CD107a surface expression was significantly upregulated, particularly with an E/T ratio of 1:1 (Fig. 4B) .
Next, we determined the effect of intratumoral T reg cells on CD107a expression on infiltrating CD8 + T cells exposed to tumor cells (Fig. 4C) . Before exposure to Raji cells, PHA-activated CD8 + T cells were cocultured either alone (i) or with infiltrating CD4 + CD25 À T cells (ii) or intratumoral T reg cells (iii). Raji cells were added to the cultures, and CD107a expression on CD8 + T cells was assessed. CD107a expression on resting CD8 + T cells exposed to Raji cells (iv), and activated CD8 + T cells without exposure to Raji cells (v) served as controls. When activated CD8 + T cells were exposed to Raji cells (i), CD107a expression increased (15 F 2%, n = 5) compared with that found on activated cells alone (v; 1.3 F 0.2%, n = 5) or on resting cells exposure to Raji cells (iv; 0.5 F 0.15%, n = 5). When intratumoral T reg cells were added to the culture, CD107a surface expression was significantly reduced (2 F 0.6%, n = 5). We saw a moderate inhibition of CD107a surface expression on activated CD8 + T cells when the cells were exposed to infiltrating CD4 + CD25 À T cells (ii; 10 F 1.6%, n = 5). These results indicate that intratumoral T reg cells attenuate CD107a surface expression on activated infiltrating CD8 + T cells during exposure to tumor cells. Intratumoral T reg cells inhibit the ability of infiltrating CD8 + T cells to lyse lymphoma B cells. Because intratumoral T reg cells inhibit the proliferation, granule production, and degranulation of infiltrating CD8 + T cells, we next wanted to determine the effect of intratumoral T reg cells on cytotoxicity of infiltrating CD8 + T cells when exposed to lymphoma B cells. We first examined the ability of resting and activated CD8 + T cells to lyse lymphoma B cell lines Raji, DoHH2, and Karpas. As shown in We then wanted to determine the effect of intratumoral T reg cells on the cytotoxic activity of activated infiltrating CD8 + T cells (Fig. 5B) . Using Raji cells as a target, we cocultured activated infiltrating CD8 + T cells treated with intratumoral T reg cells or infiltrating CD4 + CD25 À T cells at E/T ratios of 5:1, 10:1, and 25:1.
We found that activated CD8 + T cells showed significant dosedependent cytolytic activity toward Raji cells. Coculture of activated infiltrating CD8 + T cells with intratumoral T reg cells (n = 3) attenuated the cytotoxic activity against Raji cells (11 F 6.06% at E/T ratio 25:1) compared with activation-induced CD8 + T cells alone (69.8 F 10.01% at E/T ratio 25:1, P = 0.00183) or with CD4 + CD25 À cells (27.7 F 7.9% at E/T ratio 25:1, P = 0.056). In the presence of intratumoral T reg cells, the CD8 + T-cell cytolytic activity was similar to the cytolytic activity seen in unstimulated CD8 + T cells. Next, we examined the influence of intratumoral T reg cell on the cytotoxic activity of infiltrating CD8 + T cells toward autologous lymphoma B cells. As shown in Fig. 5C , coculture of infiltrating activated CD8 + T cells with intratumoral T reg cells attenuated the cytotoxic activity against autologous lymphoma B cells (9.6 F 1.62% at E/T ratio 25:1, n = 6) compared with activation-induced CD8 + T cells alone (18 F 5% at E/T ratio 25:1, P = 0.015). Coculture of infiltrating CD8 + T cells with CD4 + CD25 À T cells had minimal effect of CTL activity compared with activated CD8 + T cells alone (18 F 4.2% at E/T ratio 25:1, P = 0.497). These results indicate that intratumoral T reg cells strongly suppress the cytotoxic function of infiltrating CD8 + T cells and suggest that infiltrating CD8 + T cells could successfully destroy autologous lymphoma B cells were it not for the protective suppressive effect of intratumoral T reg cells present at the site of B-cell NHL.
Increased numbers of intratumoral T reg cells are associated with decreased infiltrating CD8 + T-cell numbers in B-cell NHL. As shown above using an in vitro assay, we observed significant attenuation of infiltrating CD8 + T-cell function by intratumoral T reg + T cells, the CD8/ CD4 ratio, as well as the frequency of intratumoral T reg cells, CD4 + CD25 + , in 22 freshly isolated biopsy specimens from patients with B-cell NHL and examined the relationship between intratumoral T reg cells and infiltrating CD8 + T-cell population as well as the value of CD8/CD4 ratio. We found that there was a strong inverse relationship between the frequency of intratumoral T reg cells and the percentage of CD8 cells in biopsy specimens (n = 22, R 2 = 0.4927, P = 0.0006; Fig. 6A ). The samples that had a high percentage of intratumoral T reg cells had a low percentage of infiltrating CD8 + T cells. Conversely, the samples that had a low percentage of intratumoral T reg cells showed a high percentage of infiltrating CD8 + T cells. Because the CD8/CD4 ratio has been used as a clinical prognostic index for patients with cancer (32), we also compared the frequency of intratumoral T reg cells with the CD8/ CD4 ratio in our samples (Fig. 6B) . Interestingly, a linear inverse relationship could be seen between intratumoral T reg cells and the CD8/CD4 ratio when the frequency of intratumoral T reg cells was <15% (n = 12, R 2 = 0.7082, P = 0.0006). However, we found that the CD8/CD4 ratio was uniformly low when the frequency of intratumoral T reg cells was >15% (n = 11, R 2 = 0.2177, P = 0.148). These findings suggest that increased numbers of T reg cells in the tumor microenvironment suppress the relative number of CD8 + T cells.
Discussion
Orchestration of an effective immune response against tumor cells is a complex process that involves numerous branches of the immune system. Subtle alterations in costimulatory molecule expression, cytokine secretion, and ineffective migration of immune cells to the inflammatory milieu can vastly alter the clearance of antigen. Recent studies by our group, as well of others, have highlighted the significance of T reg cells in this process and suggest that T reg cells contribute to the ineffective immune response observed againsttumors (3, 10, 11, 33, 34) . Much of thiswork has focused on CD4 + CD4 + T cells or has been accomplished using murine models of solid tumors. However, there is increasing literature suggesting a role for T reg cells in hematologic malignancies as well (12, (35) (36) (37) (38) .
In previous work, we have shown that intratumoral T reg cells significantly suppress the functional capabilities of autologous (Fig. 1) . However, in other systems, Foxp3 expression may not necessarily confer regulatory activity. Recent work by Gavin et al. (42) found that small amounts of Foxp3 expression could be detected in in vitro activated CD4 + and CD8 + T cells. Unlike classic regulatory T cells, these cells were unable to suppress Th1 cytokine synthesis. However, they were not able to directly determine weather or not these cells had suppressive capabilities. In our experiments, Foxp3 expression was confined to the CD4 + population and was not detected in CD8 + T cells (data not shown). Further characterization of Foxp3 expression and regulatory activity of human T cells in both the normal and malignant scenerio will hopefully shed light recent findings.
Although it has been reported that T reg cells inhibit CD8 + T-cell proliferation under several pathologic conditions, such as infection (18, 19) and transplantation (20, 21) , it was less clear how T reg cells influence CD8 + T cells in a human tumor model. We found that intratumoral T reg cells isolated from tissue biopsy specimens from patients could completely inhibit proliferation of patient-matched autologous CD8 + T cells (Fig. 2) . The inability of CD8 + T cells to proliferate in response to antigen within the tumor microenvironment may be one mechanism by which T reg cells hinder the initial steps of a normal immune response. This is in contrast to what has been seen in mouse tumor models where experiments found that T reg cells did not interfere with accumulation or division of tumorspecific CD8 + T cells (23) . The exact mechanisms that T reg cells use to inhibit proliferation of CD8 + T in a human model may therefore be unique.
Intratumoral T reg cells suppress not only the proliferation of infiltrating CD8 + T cells but also production and release of PFN and GzmB. Our in vitro experiments indicate that intratumoral T reg cells can dramatically inhibit activation-induced intracellular expression of PFN and GzmB by CD8 + T cells (Fig. 3) . We also found that a majority of intratumoral CD8 + T cells express minimal amounts of PFN and GzmB, suggesting that they are relatively inactive. Production of PFN and GzmB is essential for CD8 + T cells to function as effector cells, and it has been shown that the perforin/granzyme pathway is critical for CTL-mediated lymphoma B-cell lysis in B-cell NHL (43) . In parallel experiments, we found that expression of CD107a, a measure of degranulation, on infiltrating CD8 + T cells was also inhibited by intratumoral T reg cells (Fig. 4) . Degranulation is one of the key steps in the cytolytic process and is required for lysis of tumor cells. Our studies show that expression of CD107a on infiltrating CD8 + T cells was upregulated upon activation by PHA or exposure to tumor cells. We also found that expression of CD107a on CD8 + T cells, upon exposure to lymphoma B cells, was suppressed by intratumoral T reg cells. Inhibition of perforin and GzmB expression by infiltrating CD8 + T, as well as suppression of granule release, may therefore be an additional mechanism by which by T reg cells suppress normal CTL responses. These results are in accordance with murine studies, which have also shown that T reg cells abolish tumorspecific CD8 + T-cell cytotoxic activity (23) . The ability of T reg cells the shutdown various aspect of CTL mediated immunity is clear; however, it was still unknown weather or not intratumoral CD8 + T cells could kill autologous tumor cells and what effect T reg cells would have on this activity. As shown in Fig. 5 , our results show that CD8 + T cells from NHL tumors are functional, and that they can kill both tumor cell lines as well as autologous lymphoma B cells. When we further characterized the CD8 + T cell population, we found that the vast majority (>90%, n = 3) of infiltrating CD8 + T cells lack expression of CD45RA and CCR7, suggesting that they are effector memory cells (data not shown) and should therefore be capable of effective immune response (44) . Of note, when we phenotyped the CD8 + T-cell population in a nonmalignant hyperplastic lymph node, we found that a vast majority (>90%, n = 1) of infiltrating CD8 + T cells expressed CD45RA and CCR7, suggesting a naive phenotype (data not shown). 
Foxp3
+ suppressive T cells in aged mice (45) . Throughout our experiments, we have found no significant difference in the function and frequency of the various T-cell subpopulations, as a percentage of total T cells, among the different NHL histologic subtypes studied thus far. However, a formal analysis has not been done due to the small number of samples used in this study.
The ability of T reg cells to shutdown antitumor activity suggests that their presence in the tumor microenvironment may have significant effect on CD8 + T-cell function as well as the progression of NHL. Therefore, we next wanted to determine if the occurrence of T reg cells in NHL was related to the number of CD8 + T cells present. When we measured the percentage of CD8 + T cells and intratumoral T reg cells in biopsy specimens from patients with B-cell NHL, we found that there was a strong inverse relationship between the frequency of intratumoral T reg cells and the percentage of CD8 + cells in biopsy specimens. Taken together, these data suggest that T reg cells influence the function of CD8 + , and that increased numbers of T reg cells in the tumor microenvironment may suppress the relative number of CD8 + T cells. In summary, our data provide evidence indicating that T reg cells contribute in part to the ineffective antitumor response seen in B-cell NHL by suppressing numerous facets of the CTL response. Our findings are in accordance with recent finding is mice where regulatory T cells have been shown to suppress CTL activity (22) (23) (24) . Taken together, these data highlight the importance of the T reg cell within the tumor microenvironment and suggest that CTLs could potentially eradicate tumor cells in the absence of T reg cells. Therefore, we contend that use of novel therapies that would inhibit the function of intratumoral T reg cells will result in significant clinical benefit for patients with B-cell NHL.
